Core Viewpoint - Bio-Techne Corporation announced leadership changes, with Steve Crouse appointed as President of the Diagnostics and Spatial Biology Segment, effective March 1, 2026, succeeding Dr. Matt McManus, who will assist in the transition [1]. Leadership Changes - Dr. Matt McManus will transition from his role as President of the Diagnostics and Spatial Biology Segment on March 1, 2026, but will remain with the company temporarily to ensure a smooth transition [1]. - Steve Crouse, previously Senior Vice President of the Analytical Solutions Division, has over 20 years of experience in life sciences and has been instrumental in driving growth and launching innovative platforms at Bio-Techne [1]. Company Background - Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [1]. - The company generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide [1].